TOP TEN perturbations for 40021_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40021_at
Selected probe(set): 206842_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40021_at (206842_at) across 6674 perturbations tested by GENEVESTIGATOR:

glioma study 16 (astrocytoma) / normal brain tissue

Relative Expression (log2-ratio):1.8341217
Number of Samples:8 / 2
Experimental glioma study 16 (astrocytoma)
Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV).
Control normal brain tissue
Normal brain tissue sample from healthy donors.

CH4987655 study 1 / vehicle (DMSO) treated NCI-H1581 cell sample

Relative Expression (log2-ratio):1.697154
Number of Samples:2 / 4
Experimental CH4987655 study 1
Human lung cancer cell line NCI-H1581 treated with 1 uM of MEK inhibitor CH4987655 for 24 hours. ATC code:---
Control vehicle (DMSO) treated NCI-H1581 cell sample
Human lung cancer cell line NCI-H1581 treated with 0.1% DMSO for 24 hours.

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):-1.6448326
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

brain tumor study 1 (pilocytic astrocytoma) / brain tumor study 1 (medulloblastoma)

Relative Expression (log2-ratio):1.3980589
Number of Samples:15 / 22
Experimental brain tumor study 1 (pilocytic astrocytoma)
Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma.
Control brain tumor study 1 (medulloblastoma)
Primary tumor tissue sample from the brain of patients with medulloblastoma.

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):-1.3384352
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):1.3029594
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

CH5183284 study 1 (NCI-H1581) / vehicle (DMSO) treated NCI-H1581 cell sample

Relative Expression (log2-ratio):1.2607155
Number of Samples:4 / 4
Experimental CH5183284 study 1 (NCI-H1581)
Human lung cancer cell line NCI-H1581 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated NCI-H1581 cell sample
Human lung cancer cell line NCI-H1581 treated with 0.1% DMSO for 24 hours.

PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.2563028
Number of Samples:3 / 17
Experimental PMA study 6 (500ng/ml)
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

CD44s overexpr. study 1 / normal HEK-293 cell sample

Relative Expression (log2-ratio):1.2411833
Number of Samples:3 / 3
Experimental CD44s overexpr. study 1
Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression.
Control normal HEK-293 cell sample
Untransfected, native human embryonic kidney cell line HEK-293 cell samples.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):1.1833105
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.